Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis



Rating:

Share or cite this content

Citations should be made in the following way:
U. Costabel (Essen, Germany). Standard therapy for sarcoidosis. Annual Congress 2005 - Biological agents in the therapy of sarcoidosis

Member's Comments

No comment yet.

Related content which might interest you: Therapeutic options for sarcoidosis: old and new Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005 Year: 2005 Corticosteroid treatment in sarcoidosis Source: Eur Respir J 2006; 28: 627-636 Year: 2006 Combined immunosuppressive therapy including anti-TNFα in a treatment of severe paediatric sarcoidosis – a case report Source: Eur Respir J 2006; 28: Suppl. 50, 829s Year: 2006 Skin involvement Source: Annual Congress 2005 - Sarcoidosis: update on extrathoracic organ problems Year: 2005 Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial Source: Eur Respir J 2008; 31: 1189-1196 Year: 2008 Short- and long-term response to corticosteroid therapy in chronic beryllium disease Source: Eur Respir J 2008; 32: 687-693 Year: 2008 Sarcoidosis Source: Respipedia Article Year: 2017 The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 Efficacy and safety of modified anti-tubercular treatment(ATT) regimens in treatment of tuberculosis(TB) in patients with underlying chronic liver disease(CLD) Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Glucocorticosteroid treatment in sarcoidosis: comparison of regimens Source: Eur Respir J 2003; 22: Suppl. 45, 234s Year: 2003 Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia Source: Eur Respir J 2013; 41: 402-409 Year: 2013 The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 The future of targeted therapies for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005 The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 434s Year: 2002 Sarcoidosis, a systemic disease Source: Annual Congress 2005 - Sarcoidosis: update on extrathoracic organ problems Year: 2005 Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis Source: Eur Respir J 2011; 38: 1145-1150 Year: 2011 Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 The response to combination therapy treatment regimens in severe/difficult-to-treat asthma Source: Eur Respir J 2008; 32: 1237-1242 Year: 2008 Infliximab: An effective rescue therapy in refractory extra-pulmonary sarcoidosis Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001